ScholarIQanswers from OpenAlex & ORCID
J. Carl Barrett
ResearcherPublications, citations & collaboration network
J. Carl Barrett is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does J. Carl Barrett have?
ScholarIQindexed works
J. Carl Barrett has 572 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does J. Carl Barrett have?
ScholarIQcitation count
J. Carl Barrett has 39,328 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of J. Carl Barrett?
ScholarIQh-index
J. Carl Barrett has an h-index of 86 in OpenAlex.
What is the i10-index of J. Carl Barrett?
ScholarIQi10-index
J. Carl Barrett has an i10-index of 272 in OpenAlex.
What is the ORCID of J. Carl Barrett?
ScholarIQorcid
The ORCID for J. Carl Barrett is on the source record.
What is the OpenAlex record for J. Carl Barrett?
ScholarIQopenalex
The OpenAlex for J. Carl Barrett is on the source record.
What are the most-cited papers on J. Carl Barrett?
ScholarIQmost cited works
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M
Kenneth S. Thress, Cloud P. Paweletz, Enriqueta Felip, Byoung Chul Cho, Daniel Stetson, Brian Dougherty, Zhongwu Lai, Aleksandra Markovets, Ana Vivancos, Yanan Kuang, Dalia Ercan, Sarah E Matthews, Mireille Cantarini, J. Carl Barrett, Pasi A. Jänne, Geoffrey R. Oxnard
Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non–Small-Cell Lung Cancer
Geoffrey R. Oxnard, Kenneth S. Thress, Ryan S. Alden, Rachael Lawrance, Cloud P. Paweletz, Mireille Cantarini, James Chih‐Hsin Yang, J. Carl Barrett, Pasi A. Jänne
Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial
Amit M. Oza, David Cibula, Ana Oaknin Benzaquen, Christopher Poole, Ron H.J. Mathijssen, Gabe S. Sonke, Nicoletta Colombo, Jiří Špaček, Peter Vuylsteke, Holger W. Hirte, Sven Mahner, Marie Plante, Barbara Schmalfeldt, Helen Mackay, Jacqui Rowbottom, Elizabeth Lowe, Brian Dougherty, J. Carl Barrett, Michael Friedländer
Osimertinib As First-Line Treatment of <i>EGFR</i> Mutation–Positive Advanced Non–Small-Cell Lung Cancer
Suresh S. Ramalingam, James Chih‐Hsin Yang, Chee Khoon Lee, Takayasu Kurata, Dong‐Wan Kim, Thomas John, Naoyuki Nogami, Yuichiro Ohe, Helen Mann, Yuri Rukazenkov, Serban Ghiorghiu, Daniel Stetson, Aleksandra Markovets, J. Carl Barrett, Kenneth S. Thress, Pasi A. Jänne
Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project
Diana M. Merino, Lisa M. McShane, David Fabrizio, Vincent Funari, Shu‐Jen Chen, James R. White, Paul Wenz, Jonathan Baden, J. Carl Barrett, Ruchi Chaudhary, Li Chen, Wangjuh Chen, Jen‐Hao Cheng, Dinesh Cyanam, Jennifer S. Dickey, Vikas Gupta, Matthew D. Hellmann, Elena Helman, Yali Li, Joerg Maas, Arnaud Papin, Rajesh Patidar, Katie Quinn, Naiyer A. Rizvi, Hongseok Tae, Christine K. Ward, Mingchao Xie, Ahmet Zehir, Chen Zhao, Manfred Dietel, Albrecht Stenzinger, Mark Stewart, Jeff Allen